Baseline patient characteristics for the double-blind study and longterm study intention-to-treat population.
| Double-blind Study | Longterm Study | ||
|---|---|---|---|
| Characteristics | Civamide Cream 0.075%, n = 344 | Civamide Cream 0.01% (control), n = 351 | Civamide Cream 0.075%, n = 351 |
| Age, yrs, p = 0.89 | |||
| Mean | 61.3 | 61.4 | 61.8 |
| Median | 62 | 62 | 62 |
| Range | 39–75 | 40–76 | 40–76 |
| Sex, n (%), p = 0.81 | |||
| Women | 230 (67) | 238 (68) | 234 (67) |
| Men | 114 (33) | 113 (32) | 117 (33) |
| Race, n (%), p = 0.296 | |||
| American Indian or Alaskan native | 4 (1) | 0 (0) | 2 (1) |
| Asian or Pacific Islander | 4 (1) | 6 (2) | 3 (1) |
| Black, not of Hispanic origin | 65 (19) | 58 (17) | 76 (22) |
| Hispanic | 13 (4) | 10 (3) | 12 (3) |
| White, not of Hispanic origin | 254 (74) | 274 (78) | 255 (73) |
| Other | 1 (0) | 2 (1) | 1 (0) |
| Unknown | 2 (1) | ||
| Weight, kg, p = 0.61 | |||
| Mean | 85.6 | 86.3 | 87.3 |
| Median | 85 | 86 | 87 |
| Range | 49–136 | 51–138 | 52–215 |
| Height, cm, p = 0.73 | |||
| Mean | 168.0 | 166.7 | NA |
| Median | 168 | 165 | |
| Range | 145–197 | 142–195 | |
| BMI, p = 0.29 | |||
| Mean | 30.3 | 30.7 | NA |
| Median | 30 | 30 | |
| Range | 19–39 | 18–41 | |
NA: not applicable; BMI: body mass index.